Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at N...( NicVAX Supports Statistically Signif...),Health

NicVAX Supports Statistically Significant Point Prevalence and Continuous Abstinence by Dose, Schedule and Antibody Response; Nabi to Host Conference

Call Today

BOCA RATON, Fla., Sept. 5 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals (Nasdaq: NABI) today announced nine-month data from its ongoing trial of NicVAX(R) (Nicotine Conjugate Vaccine), the company's innovative and proprietary investigational vaccine being developed to treat nicotine addiction and prevent smoking relapse. These nine-month data demonstrate NicVAX efficacy in supporting statistically significant and continuous abstinence rates by dose as well as by antibody response. The nine-month data also have enabled Nabi to determine what it believes is the most effective dose and schedule for NicVAX and determine the antibody concentration threshold for clinical efficacy. In May 2007, Nabi announced this trial's six-month data -- a statistically significant number of patients with a high anti-nicotine antibody response met the trial's primary endpoint of eight weeks of continuous abstinence between weeks 19-26.

NicVAX Nine-Month Data Key Findings

-- High antibody responders (top 30%) continued to show statistically

significant abstinence at nine months:

-- 9-Month continuous abstinence rate: NicVAX=20% (12/61, p=0.0076) vs.

Placebo=6% (6/100)

-- Statistically significant dose response observed for continuous

abstinence at six and nine months for Schedule 2, 200 and 400 microgram

doses in the intent to treat population:

-- 9-Month continuous abstinence: NicVAX 400 micrograms =18% (9/51,

p=0.0047), Placebo=4% (4/100)

-- 9-
'/>"/>